Weak overseas OEM orders and sales from Siemens
First written in FY2017-Q1. 9 of 30 entries say "Worsened", first in FY2017-Q2. Latest entry: FY2025-H1.
Jeol moved to the "Worse" side of this theme in 2023.
0 other companies' latest entry also says "Mitigated".
- FY2025-H1MitigatedAnnual report
「Orders and sales in Japan remained strong, but both orders and sales overseas remained at low levels. As a result, sales in this business amounted to ¥6,411 million, down 12.9% year on year.」
Although domestic orders and sales were strong, weakness overseas continued. Business sales declined 12.9% year on year, narrowing slightly from the 13.5% decline in the second quarter of the previous fiscal year. - FY2024WorsenedAnnual report
「Inquiries for automated biochemical analyzers in the domestic market remained solid. In overseas markets, however, both orders and sales remained at low levels due in part to China's domestic substitution policies and other factors. As a result, sales in this business amounted to ¥15,312 million, down 16.9% from the previous fiscal year.」
Although domestic inquiries were reportedly solid, weakness in overseas markets continued, and the medical equipment business posted a 16.9% full-year decline in revenue. - FY2024-Q3WorsenedAnnual report
「Orders and sales in Japan remained solid, but overseas orders and sales remained at low levels due in part to China's domestic substitution policies and other factors. As a result, sales in this business amounted to ¥10,901 million, down 16.1% year on year.」
Although Japan remained solid, overseas orders and sales fell to low levels due to China's domestic substitution policies and other factors, and the rate of decline in revenue for the medical equipment business widened to 16.1% year on year. - FY2024-Q2MitigatedAnnual report
「Orders and sales in Japan remained strong, but both orders and sales overseas remained at low levels. As a result, sales in this business amounted to ¥7,358 million, down 13.5% year on year.」
Although sluggish overseas orders and sales continued, the rate of decline in revenue for the medical equipment business narrowed from 24.6% in the first quarter of the previous fiscal year to 13.5%. - FY2024-Q1WorsenedAnnual report
「Orders and sales, particularly for automated biochemical analyzers, remained at low levels. As a result, sales in this business amounted to ¥3,203 million, down 24.6% year on year.」
In addition to the previous overseas market and OEM trends, overall orders and sales, particularly for automated biochemical analyzers, fell to low levels, and the medical equipment business declined 24.6% year on year. - FY2023WorsenedAnnual report
「Inquiries for automated biochemical analyzers in the domestic market remained solid. In overseas markets, however, both orders and sales remained at low levels due in part to the impact of China's lockdowns. As a result, sales in this business amounted to ¥18,430 million, down 4.3% from the previous fiscal year.」
Although domestic inquiries remained solid, orders and sales in overseas markets fell to low levels due to China's lockdowns and other factors, resulting in a full-year decline in revenue for the medical equipment business. - FY2023-Q3WorsenedAnnual report
「Inquiries, particularly for automated biochemical analyzers in the domestic market, remained solid. In overseas markets, however, both orders and sales remained at low levels due in part to the impact of China's lockdowns. As a result, sales in this business amounted to ¥12,995 million, down 9.4% year on year.」
Although inquiries in the domestic market were reportedly solid, overseas markets, previously considered strong, saw orders and sales fall to low levels due to China's lockdowns and other factors, resulting in lower revenue for the medical equipment business. - FY2023-Q2Continued weak domestic and strong overseas performanceAnnual report
「Orders and sales overseas remained strong, but both orders and sales in the domestic market remained at low levels. As a result, sales in this business amounted to ¥8,504 million, down 9.1% year on year.」
The mix of strong overseas orders and sales and low domestic market performance continued. The medical equipment business as a whole declined 9.1% year on year. - FY2023-Q1Shift in the mix from weak domestic and solid overseas performanceAnnual report
「In overseas markets, inquiries and sales, particularly for automated biochemical analyzers, remained solid. In Japan, however, sales remained at low levels. As a result, sales in this business amounted to ¥4,245 million, down 5.4% year on year.」
The explanation has shifted from sluggish overseas OEM business to a mix of solid overseas performance and low domestic performance. The medical equipment business as a whole declined 5.4% year on year. - FY2022-Q3AdvancedAnnual report
「Sales remained strong, particularly for automated biochemical analyzers overseas. As a result, sales in this business amounted to ¥14,343 million, up 31.5% year on year.」
Compared with the previous references to sluggish overseas demand and the impact of infectious diseases, sales were strong, particularly for automated biochemical analyzers overseas, and the medical equipment business posted a 31.5% year-on-year increase in revenue. - FY2022-Q2AdvancedAnnual report
「Orders and sales remained strong in both Japan and overseas markets. As a result, sales in this business amounted to ¥9,354 million, up 29.0% year on year.」
Compared with the previous references to sluggish overseas demand and demand declines caused by infectious diseases, orders and sales were strong in both Japan and overseas markets, and the medical equipment business posted a 29.0% year-on-year increase in revenue. - FY2021Change in the composition of overseas demandAnnual report
「Sales of automated biochemical analyzers for overseas markets remained solid, particularly in emerging markets.」
The explanation has shifted from sluggish overseas OEM business with Siemens to solid sales of automated biochemical analyzers for overseas markets, particularly in emerging markets. Domestic sales, however, declined due to the impact of infectious diseases. - FY2021-Q3MitigatedAnnual report
「Although sales of automated biochemical analyzers overseas increased, overall sales remained at low levels because blood testing for medical checkups and other purposes declined due to the impact of COVID-19. As a result, sales in this business amounted to ¥10,908 million, down 9.8% year on year.」
Although overseas sales of automated biochemical analyzers increased, the decline in blood testing for medical checkups and other purposes continued. The rate of decline in business sales narrowed from 12.2% in the previous quarter to 9.8%. - FY2021-Q2Demand decline due to infectious diseases becomes apparentAnnual report
「Although sales of automated biochemical analyzers overseas increased, overall sales remained at low levels because blood testing for medical checkups and other purposes declined due to the impact of COVID-19. As a result, sales in this business amounted to ¥7,253 million, down 12.2% year on year.」
Although overseas sales of automated biochemical analyzers increased, the decline in blood testing for medical checkups and other purposes was newly identified as a specific factor, and the medical equipment business declined 12.2% year on year. - FY2021-Q1Increase in overseas sales; impact of infectious diseasesAnnual report
「Although sales of automated biochemical analyzers overseas increased, overall sales remained at low levels due to the impact of COVID-19. As a result, sales in this business amounted to ¥3,708 million, down 6.7% year on year.」
Compared with the previous explanation that overseas OEM orders and sales were sluggish, sales of automated biochemical analyzers overseas increased, while sales for the medical equipment business as a whole were low due to the impact of COVID-19. - FY2020-Q3RestatedAnnual report
「Inquiries and sales, particularly for automated biochemical analyzers in the domestic market, both remained solid. In overseas markets, however, both orders and sales remained at low levels.」
Although inquiries and sales in the domestic market were solid, orders and sales in overseas markets continued to remain at low levels. - FY2020-Q2RestatedAnnual report
「Inquiries and sales, particularly for automated biochemical analyzers in the domestic market, remained solid. In overseas markets, however, orders and sales remained at low levels.」
Although inquiries and sales in the domestic market were solid, orders and sales in overseas markets continued to remain at low levels. - FY2020-Q1RestatedAnnual report
「Inquiries, particularly for automated biochemical analyzers in the domestic market, remained strong, and sales were solid. Overseas, however, sales to OEM supply customers remained at low levels.」
Although the domestic market was strong, sales to overseas OEM supply customers continued to remain at low levels. - FY2019RestatedAnnual report
「Sales of automated biochemical analyzers in Japan and immunoassay analyzers supplied to Fujirebio as an OEM customer remained strong. Overseas, however, orders and sales from Siemens, an OEM supply customer, remained at low levels.」
Although Japan and Fujirebio performed well, overseas OEM orders and sales to Siemens continued to remain at low levels. - FY2019-Q3RestatedAnnual report
「Sales of automated biochemical analyzers in the domestic market remained solid. In overseas markets, however, sales remained at low levels due to a decline in OEM sales. As a result, sales in this business amounted to ¥12,299 million, down 9.3% year on year.」
Although the domestic market was reportedly solid, sales in overseas markets continued to remain at low levels due to a decline in OEM sales. - FY2019-Q2RestatedAnnual report
「Inquiries, particularly for automated biochemical analyzers in the domestic market, remained strong, and sales were solid. Overseas, however, orders and sales from Siemens, an OEM supply customer, remained at low levels. As a result, sales in this business amounted to ¥8,314 million, down 2.9% year on year.」
Although inquiries in the domestic market were reportedly strong, overseas OEM orders and sales to Siemens continued to remain at low levels. - FY2019-Q1RestatedAnnual report
「In the domestic market, inquiries, particularly for automated biochemical analyzers, remained strong, and sales remained firm. Meanwhile, overseas orders and sales from Siemens, an OEM supply partner, remained at a low level. As a result, revenue from this business was ¥4,278 million, up 5.2% year on year.」
Although inquiries in the domestic market were strong and the business as a whole posted higher revenue, overseas OEM orders and sales from Siemens continued to remain at low levels. - FY2018WorsenedAnnual report
「Sales of automated biochemical analyzers for the domestic market and immunoassay systems for Fujirebio, an OEM supply partner, remained strong. Meanwhile, overseas orders and sales from Siemens, an OEM supply partner, remained at a low level. As a result, revenue from this business was ¥19,382 million, down 10.4% from the previous fiscal year.」
While domestic sales and sales to Fujirebio were strong, sales to Siemens remained at a low level, and full-year revenue declined 10.4% year on year. - FY2018-Q3WorsenedAnnual report
「Sales of automated biochemical analyzers for the domestic market and immunoassay systems for Fujirebio, an OEM supply partner, remained strong. Meanwhile, overseas orders and sales from Siemens, an OEM supply partner, remained at a low level. As a result, revenue from this business was ¥13,564 million, down 9.2% year on year.」
While domestic sales and sales to Fujirebio were described as strong, sales to Siemens remained at a low level, and revenue from the Medical Equipment Business declined 9.2% year on year. - FY2018-Q2MitigatedAnnual report
「Sales of automated biochemical analyzers for the domestic market and immunoassay systems for Fujirebio, an OEM supply partner, remained strong. Meanwhile, overseas orders and sales from Siemens, an OEM supply partner, remained at a low level. As a result, revenue from this business was ¥8,560 million, down 7.6% year on year.」
Domestic sales and sales to Fujirebio were described as strong, while sales to Siemens remained at a low level. The decline in business revenue narrowed from 15.5% in the previous quarter to 7.6%. - FY2018-Q1WorsenedAnnual report
「Sales of automated biochemical analyzers for the domestic market and immunoassay systems for Fujirebio, an OEM supply partner, remained strong. Meanwhile, overseas orders and sales from Siemens, an OEM supply partner, remained at a low level. As a result, revenue from this business was ¥4,068 million, down 15.5% year on year.」
While domestic sales and sales to Fujirebio were described as strong, overseas OEM orders and sales from Siemens remained at a low level, and business revenue declined 15.5% year on year. - FY2017MitigatedAnnual report
「Sales of automated biochemical analyzers for the domestic market remained firm. Overseas, orders and sales from Siemens, an OEM supply partner, remained somewhat weak. Revenue from this business was ¥21,624 million, down 7.9% from the previous fiscal year.」
Although weak overseas OEM orders and sales from Siemens continued, the decline in revenue narrowed from 9.5% in the cumulative third quarter to 7.9% for the full year. - FY2017-Q3MitigatedAnnual report
「Sales of automated biochemical analyzers for the domestic market remained firm. Overseas, orders and sales from Siemens, an OEM supply partner, remained somewhat weak. As a result, revenue from this business was ¥14,947 million, down 9.5% year on year.」
Although weak overseas OEM orders and sales from Siemens continued, the decline in revenue from the Medical Equipment Business narrowed from 17.1% in the cumulative second quarter to 9.5%. - FY2017-Q2WorsenedAnnual report
「Sales of automated biochemical analyzers for the domestic market remained firm. Overseas, orders and sales from Siemens, an OEM supply partner, remained somewhat weak. As a result, revenue from this business was ¥9,264 million, down 17.1% year on year.」
Weak overseas OEM orders and sales from Siemens continued, and the decline in revenue from the Medical Equipment Business widened from 2.9% in the previous quarter to 17.1%. - FY2017-Q1First statedAnnual report
「Sales of automated biochemical analyzers for the domestic market remained firm. Overseas, orders and sales from Siemens, an OEM supply partner, remained somewhat weak. As a result, revenue from this business was ¥4,815 million, down 2.9% year on year.」
It reports firm domestic sales, while overseas OEM orders and sales from Siemens, an OEM supply partner, remained weak, and revenue from the Medical Equipment Business declined.